These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 6886045)

  • 21. Correlation between vasopressin baseline and TSH-blunting in depressives.
    Lenzinger E; Meszaros K; Hornik K; Parzer P; Hollerer E; Langer G; Resch F; Legros JJ
    Biol Psychiatry; 1996 Mar; 39(5):341-5. PubMed ID: 8704065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The antidepressant response to tricyclics in major depressives is accelerated with adjunctive use of methylphenidate.
    Gwirtsman HE; Szuba MP; Toren L; Feist M
    Psychopharmacol Bull; 1994; 30(2):157-64. PubMed ID: 7831449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Methylphenidate augmentation of fluvoxamine for treatment-resistant depression: a case report and review literature].
    Buhagiar K; Cassar J
    Turk Psikiyatri Derg; 2007; 18(2):179-83. PubMed ID: 17566884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute effects of cold on blood levels of growth hormone, cortisol, and thyrotropin in man.
    Golstein-Golaire J; Vanhaelst L; Bruno OD; Leclercq R; Copinschi G
    J Appl Physiol; 1970 Nov; 29(5):622-6. PubMed ID: 5482397
    [No Abstract]   [Full Text] [Related]  

  • 25. Responses to mCPP stimulation in depressed patients.
    Thakore JH
    Am J Psychiatry; 1995 Dec; 152(12):1833-4; author reply 1834-5. PubMed ID: 8526261
    [No Abstract]   [Full Text] [Related]  

  • 26. Growth hormone, cortisol and prolactin responses to physical exercise: higher prolactin response in depressed patients.
    Kiive E; Maaroos J; Shlik J; Tõru I; Harro J
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Sep; 28(6):1007-13. PubMed ID: 15380861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hormonal differences between psychotic and non-psychotic melancholic depression.
    Contreras F; Menchon JM; Urretavizcaya M; Navarro MA; Vallejo J; Parker G
    J Affect Disord; 2007 Jun; 100(1-3):65-73. PubMed ID: 17098292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychopharmacology of attention deficit disorder: pharmacokinetic, neuroendocrine, and behavioral measures following acute and chronic treatment with methylphenidate.
    Shaywitz SE; Hunt RD; Jatlow P; Cohen DJ; Young JG; Pierce RN; Anderson GM; Shaywitz BA
    Pediatrics; 1982 Jun; 69(6):688-94. PubMed ID: 7079034
    [No Abstract]   [Full Text] [Related]  

  • 29. A rapid response with psychostimulants in the treatment of depressed persons with medical illnesses.
    Roy M; Bernier J
    Can J Psychiatry; 1999 Apr; 44(3):283-4. PubMed ID: 10225132
    [No Abstract]   [Full Text] [Related]  

  • 30. Response to growth hormone in attention deficit hyperactivity disorder: effects of methylphenidate and pemoline therapy.
    Rao JK; Julius JR; Breen TJ; Blethen SL
    Pediatrics; 1998 Aug; 102(2 Pt 3):497-500. PubMed ID: 9685452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What are the pharmacologic considerations when treating depression in patients with HIV infection?
    Swenson JR
    J Psychiatry Neurosci; 1998 May; 23(3):200. PubMed ID: 11499431
    [No Abstract]   [Full Text] [Related]  

  • 32. Thyroid function in depression.
    Chakrabarti K; Singh PM; Joshi SP
    Nepal Med Coll J; 2006 Mar; 8(1):47-8. PubMed ID: 16827091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methylphenidate in diagnosing conversion symptoms.
    Burstein A
    J Clin Psychiatry; 1985 Mar; 46(3):110-1. PubMed ID: 3972779
    [No Abstract]   [Full Text] [Related]  

  • 34. Endocrine function is altered in chronic migraine patients with medication-overuse.
    Rainero I; Ferrero M; Rubino E; Valfrè W; Pellegrino M; Arvat E; Giordano R; Ghigo E; Limone P; Pinessi L
    Headache; 2006 Apr; 46(4):597-603. PubMed ID: 16643554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The effect of a single electroconvulsive shock on pituitary-thyroid-adrenal-gonadal axis function in men with severe depression--preliminary report].
    Motta E; Ostrowska Z; Kazibutowska Z; Paluch M; Płonka J; Gołba A
    Psychiatr Pol; 2005; 39(3):469-79. PubMed ID: 16149757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The plasma level of methylphenidate in the single-dose oral methylphenidate test.
    Van Kempen GM; Goekoop JG; Jong HB; Edelbroek PM; de Wolff FA
    Biol Psychiatry; 1990 Oct; 28(7):638-40. PubMed ID: 2223930
    [No Abstract]   [Full Text] [Related]  

  • 37. Cortisol synthesis inhibition: a new treatment strategy for the clinical and endocrine manifestations of depression.
    Thakore JH; Dinan TG
    Biol Psychiatry; 1995 Mar; 37(6):364-8. PubMed ID: 7772644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychologic and neuroendocrine response to methylphenidate.
    Brown WA
    Arch Gen Psychiatry; 1977 Sep; 34(9):1103-8. PubMed ID: 901139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Akinesia and mutism following a methylphenidate challenge test.
    Wiener J; Kennedy S
    J Clin Psychopharmacol; 1985 Aug; 5(4):231-3. PubMed ID: 4019811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methylphenidate for depressive disorders in cancer patients. An alternative to standard antidepressants.
    Fernandez F; Adams F; Holmes VF; Levy JK; Neidhart M
    Psychosomatics; 1987 Sep; 28(9):455-61. PubMed ID: 3432548
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.